CoChat

In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes

Open access
Schiavon, Michele, Visentin, Roberto, Giegerich, Clemens, Sieber, Jochen, Dalla Man, Chiara, Cobelli, Claudio, Klabunde, Thomas · 2020 · Diabetes Technology & Therapeutics
Cited by 19

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Background: Second-generation long-acting insulin glargine 300 U/mL (Gla-300) and degludec 100 U/mL (Deg-100) provide novel basal insulin therapies for the treatment of type 1 diabetes (T1D). Both offer a flatter pharmacokinetic (PK) profile than the previous generation of long-acting insulins, thus improving glycemic control while reducing hypoglycemic events. This work describes an in silico head-to-head comparison of the two basal insulins on 24-h glucose profiles and was used to guide the design of a clinical trial. Materials and Methods: The Universities of Virginia (UVA)/Padova T1D simulator describes the intra-/interday variability of glucose-insulin dynamics and thus provides a robust bench-test for assessing glucose control for basal insulin therapies. A PK model describing subcutaneous absorption of Deg-100, in addition to the one already available for Gla-300, has been developed based on T1D clinical data and incorporated into the simulator. One hundred in silico T1D subjects received a basal insulin dose (Gla-300 or Deg-100) for 12 weeks (8 weeks uptitration, 4 weeks stable dosing) by morning or evening administration in a basal/bolus regimen. The virtual patients were uptitrated to their individual doses with two different titration rules. Results: The last 2-week simulated continuous glucose monitoring data were used to calculate various outcome metrics for both basal insulin treatments, with primary outcome being the percent time in glucose target (70–140 mg/dL). The simulations show no statistically significant difference for Gla-300 versus Deg-100 in the main endpoints. Conclusions: This work suggests comparable glucose control using either Gla-300 or Deg-100 and was used to guide the design of a clinical trial intended to compare second-generation long-acting insulin analogues.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/dia.2020.0027

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 22

  1. 10.1007/s11892-017-0926-8 · DOI
  2. 10.1016/j.diabet.2013.09.003 · DOI
  3. 10.1111/dom.12782 · DOI · Paper page
  4. 10.1080/17425255.2016.1202916 · DOI
  5. 10.1007/s40265-013-0051-1 · DOI
  6. 10.1517/17425255.2015.1058779 · DOI · Paper page
  7. 10.2337/dc15-0249 · DOI · Paper page
  8. 10.1111/dom.12938 · DOI · Paper page
  9. 10.1016/j.diabet.2017.10.001 · DOI · Paper page
  10. 10.1177/1932296817731422 · DOI · Paper page
  11. 10.2337/dc18-0559 · DOI · Paper page
  12. 10.1109/TBME.2019.2919250 · DOI
  13. 10.1109/TBME.2017.2652062 · DOI · Paper page
  14. 10.1109/TBME.2017.2784101 · DOI · Paper page
  15. Cobelli C Carson ER: Introduction to Modeling of Metabolic in Physiology and Medicine 2nd ed. San Diego CA: Academic Press 2019. · doi:10.1016/b978-0-12-815756-5.00001-1
  16. 10.1152/ajpendo.00473.2004 · DOI · Paper page
  17. 10.2337/dc16-0684 · DOI · Paper page
  18. 10.1109/TBME.2017.2746340 · DOI · Paper page
  19. 10.1155/2015/281589 · DOI
  20. 10.1111/dom.12416 · DOI · Paper page
  21. 10.1080/10273660008833060 · DOI · Paper page
  22. 10.1177/0954411917702931 · DOI · Paper page

Cited by

See all 19

Metadata

Authors
Schiavon, M., Visentin, R., Giegerich, C., Sieber, J., Dalla Man, C., Cobelli, C., & Klabunde, T.
Venue
Diabetes Technology & Therapeutics
Published
2020-08-01
Volume
22
Issue
8
Pages
553-561
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W2907081153
Cited by
19
References
17
FWCI
2.23
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.